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randomized controlled trials (RCTs), with 19 including OS as an endpoint. Seven of 
these 19 indications had statistically significant OS data based on the most recent 
data cut included in the manufacturer’s submission to pCODR, while the remaining 
12 either did not have statistically significant OS data or the OS data were immature 
(i.e., median OS not yet reached) at the time of submission. More than half of the 12 
submissions with non-significant OS trial data allowed cross-over in the trial (n= 9) 
thereby potentially confounding the clinical benefit of the active therapy. Of the 19 
positive recommendations which had an RCT design and assessed OS as an endpoint, 
progression-free survival (PFS) was statistically significant with or without additional 
clinically or statistically significant secondary endpoints. ConClusions: This study 
highlights that positive pCODR recommendations may be made in the absence of a 
clear OS benefit, provided strong PFS and or additional endpoint data exist.
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BACkground: In 2010, the permanent national oncology-specific drug review pro-
cess, pan-Canadian Oncology Drug Review (pCODR), was established to assess the 
clinical evidence and cost-effectiveness of new cancer drugs and provide recom-
mendations to the provinces (except Quebec) and territories to guide their drug 
funding decisions. oBjeCtives: This study sought to identify characteristics and 
decision patterns of the pCODR recommendations. Methods: Twenty-eight rec-
ommendations, covering 33 requested populations, publicly accessible at www.
pcodr.ca were reviewed since pCODRs operation: 13 July 2011 - 9 December 2013. 
Additional information was obtained from the www.reimbursementdecisions.com 
database. results: Of the twenty-four positive recommendations for coverage, 
three suggested a more limited patient population than the one requested. Four 
population funding requests received positive recommendations for the requested 
population without conditions. In seventeen cases, positive recommendations for 
the requested population were made conditional on improvement of cost-effective-
ness ratios. Nine negative recommendations were made due to: a) limitations in evi-
dence from phase two trials; b) modest progression-free survival, lack of statistically 
significant overall survival, lack of quality of life data and poor cost-effectiveness, 
and/or; c) unclear clinical benefit and an unacceptable cost-effectiveness model. 
Many economic reviews by pCODR included re-analyses of the cost-effectiveness 
ratios which in some cases had substantial impact on cost-effectiveness. The most 
common changes from the submitted analyses where limiting product benefit 
post-progression, time horizon reductions, or changes to post-progression mortal-
ity risk. ConClusions: Most submissions resulted in a positive funding recom-
mendation. The positive conditional pCODR recommendations support a continued 
provincial product listing agreement structure that includes rebates to lower cost-
effectiveness. The economic re-analyses of the post-progression survival benefit 
indicates a need for manufacturers to provide comprehensive consideration of 
uncertainty surrounding such benefits in the submitted cost-effectiveness analysis.
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oBjeCtives: Understand how conditionally approved (CA) compounds in the EMA 
have performed in reimbursement assessment. Findings will inform current adap-
tive licensing initiatives. Methods: EMA EPAR reports were analysed to identify 
CA compounds from 2006−2013. HTA reports from national reimbursement authori-
ties of the UK (NICE, SMC), France (HAS), Germany (G-BA) and Italy (AIFA) were also 
analysed to understand reimbursement status of these products. results: 20 CA 
compounds were identified: 11 with current CA status, 7 fully approved and 2 with-
drawn. Approval was based upon strength of clinical data from PII/PIII studies. In 
France, 86% of CA indications were reimbursed, most with an ASMR V. In Italy, 62% 
of CA indications were reimbursed. Risk sharing agreements (RSA) were used in at 
least 38% of approvals. In Germany, approximately 50% of CA products licensed after 
AMNOG were reimbursed. In the UK, only 6 CA products received a positive NICE 
recommendation, 5 under RSAs to fulfil the cost-effectiveness criteria. CA is granted 
on limited clinical evidence. Countries using a therapeutic-benefit assessment (e.g. 
France) reimbursed more CA compounds than cost-effectiveness (CE) driven coun-
tries (e.g. UK). RSA is a key tool to win reimbursement in cost-effectiveness countries 
where high ICER thresholds impeded reimbursement (Bosutinib) or insufficient clini-
cal data (Pixantrone). Positive reimbursement decisions were driven by robust clinical 
data in orphan or small indications with limited therapies. Strategies employed by 
companies to overcome payer concerns include: 1) Initial restriction of compound 
approval to small high unmet need subpopulations; 2) Performance or financial risk 
sharing arrangements; 3) On-going evidence development plans. ConClusions: 
Reimbursement outcomes for CA compounds are variable across the EU. This is due 
to either clinical or economic uncertainties from evidence produced. To deal with 
these uncertainties, agreed mechanisms for continual evidence development and RSA 
implementations should be incorporated into on-going adaptive licensing initiatives.
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oBjeCtives: The objective of this study is to compare the HTA decisions of oncology 
products in France and Germany and provide insight into the most important asset 
value attributes that characterise a positive appraisal in these markets. Methods: 
We analysed the G-BA and the HAS assessments of 11 oncology products published 
conducted in health maintenance organizations were more likely to have a PSA-
screening, compared to physician group settings. General practitioners were more 
likely to receive PSA-screening compared to other types of specialists. Interactions 
between race and insurance type were not significant. ConClusions: Hispanics 
and individuals insured by Medicaid are less likely to receive PSA-screening dur-
ing an ambulatory care office-visit for a PHE. Efforts to improve access to cancer-
screening services are warranted for these groups. It is necessary to consider the 
differential impact of PCa-screening policies on medically underserved populations.
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oBjeCtives: To estimate the annual financial burden of cancer care in the 
United States and to study the effects of cancer on total health care of the coun-
try. Methods: Direct medical cancer care costs of for the years 2008-2011 were 
estimated using the household component of the Medical Expenditure Panel Survey 
(MEPS), a nationally representative survey that includes self-reported health care 
utilization and expenditures for the US civilian non-institutionalized population. 
The likelihood of having a cancer diagnosis by age, race and insurance status and 
other variables were also assessed. results: Aggregate cost of cancer in the US 
increased from $183 billion in 2008 to $236 billion in 2011. While total out-of-pocket 
(OOP) costs per cancer case decreased from $1,419.43 in 2008 to $1,254.77 in 2011, 
total cost per-case increased from $10,461.66 to $12,583.69 over 2008 to 2011. The 
OOP and total medical care expenditures per case in 2008 were $1,560.54 and 
$11501.69 respectively in 2011 prices using Urban Medical Consumer Price Index. 
OOP per case declined at an annual rate of 7.3% while the total direct cost increased 
at an annual rate of about 3%. Whites, females and 45-64 year olds were more likely 
to have a cancer diagnosis and most cancer care costs were covered by private insur-
ers. Geographical location was not associated with cancer diagnosis although the 
southern region has the highest concentration. ConClusions: Our study confirms 
that cancer is a significant cost driver of the US health care system. Due to expected 
increase in the number of incident cases and survival rate, total cost of cancer is 
likely to increase rapidly over the next decade. With the implementation of the 
Affordable Care Act, burden of cancer care costs on taxpayers will increase due to 
higher insurance coverage and lower OOP cost.
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oBjeCtives: Increasing use of imaging procedures has raised concerns about the 
risk of cancer due to repeated exposure to low-ionizing radiation. We developed an 
online radiation risk assessment tool to project the lifetime attributable risk (LAR) 
of cancer incidence following repeated exposure to imaging procedures. Methods: 
We developed a risk projection model to assess radiation exposure from imaging 
procedures, to estimate the lifetime attributable risk (LAR) of cancer incidence and 
95% uncertainty limits (UL), according to age, gender, and imaging type. We used the 
“linear no-threshold” models (extrapolation of risk associated with high-dose ion-
izing radiation to low-dose exposure). The model has been adjusted using Canadian 
data to reflect the Canadian population. results: Selected simulation results are 
presented. The LAR of cancer incidence for a 50 and 70 year old male, exposed to 
a single coronary angiogram is 11 (95% UL: 6-22) and 6 (3-12) per 10,000 exposed, 
respectively. As the number of coronary angiograms increased from one to five over 
time, the cancer risk increased to 54 (27-106) and 26 (14-52) per 10,000, respectively. 
As age increases the excess lifetime risk of cancer decreases. The excess lifetime risk 
of cancer is higher for females than for males. The LAR of cancer for a 70 year old 
male and female, exposed to a computed tomography (CT) for suspected stroke is 4 
(2-8) and 5 (3-10) per 10,000, respectively. As the number of CT scans increased from 
one to five, the total risk of cancer increased to 17 (8-33) and 23 (12-43) per 10,000, 
respectively. ConClusions: Patients are rarely aware of radiation risk. Physicians 
often underestimate the magnitude of radiation doses arising from imaging proce-
dures. An online, interactive model might facilitate the decision making process, 
leading to more informed decisions and improved clinical outcomes.
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oBjeCtives: Overall survival (OS) data for cancer products is an important end-
point to payers. This study sought to examine (1) what proportion of positive reim-
bursement recommendations by the pan-Canadian Oncology Drug Review (pCODR) 
occurred despite unavailable statistically significant overall survival data, and (2) 
the proportion of negative recommendations that noted a lack of overall survival 
data as a contributing factor. Methods: Recommendations publicly accessible at 
www.pcodr.ca and reimbursementdecisions.com were reviewed for the period 13 July 
2011 – 9 December 2013. results: During this time period, 28 submissions contain-
ing 32 oncology-specific indications were deliberated on by the pCODR committee. 
Of the eight indications that received a negative recommendation, only one had 
statistically significant overall- and progression-free survival data. A total of 24 indi-
cations received positive recommendations. Of these, two were based on single-arm 
Phase II clinical trials. The remaining 22 positive recommendations were based on 
